Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer adenocarcinoma. The FDA's written response to the company's Type C meeting request provides a clearer regulatory path forward, including a strategy focused on the EGFR exon 21 L858R-mutant never-smoker population, where emerging data suggest LP-300 may offer differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure.
The HARMONIC trial is a randomized, double-blind, placebo-controlled study assessing LP-300 plus standard chemotherapy versus chemotherapy alone in never-smoker patients with advanced lung adenocarcinoma who have progressed on tyrosine kinase inhibitor therapy. The FDA's support for the amendments is a significant milestone for Lantern Pharma, as it validates the company's precision oncology approach and the potential of LP-300 to address an unmet medical need in this specific patient subgroup.
Lantern Pharma is a clinical-stage precision oncology company that leverages artificial intelligence, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. The company's clinical pipeline includes LP-184, LP-284, and LP-300, with LP-300 being evaluated in the HARMONIC trial. Additionally, Lantern recently launched withZeta.ai, a multi-agentic AI co-scientist platform now commercially available as a subscription-based research platform for the global biomedical community, representing a new revenue stream.
The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. For more information on Lantern Pharma, visit the company's newsroom at https://ibn.fm/LTRN.
